Laxxon Medical
Laxxon Medical develops 3D screen printing technology (SPID) for structured tablets enabling controlled drug release.
- CEO / Founder
- Helmut Kerschbaumer
- Team Size
- 20
- Stage
- Growth Stage
- Total Funding
- $9M
- Latest Round
- Strategic Investment
- Key Investors
- Evonik Venture Capital, Crown Fund, German Accelerator, Bavarian Capital Management, bm-t Beteiligungsmanagement Thuringen
Technology & Products
Key Products
SPID Technology Platform, 3D Screen Printed Tablets, Contract development services
Technological Advantage
Patented 3D screen printing faster than traditional 3D printing; enables combination drugs in single tablet
Differentiation
Value Proposition
SPID technology enables mass production of structured tablets with multiple active ingredients and controlled release profiles.
How They Differentiate
Industrial-scale throughput vs. competitors single-unit production; screen printing vs. extrusion
Market & Competition
Target Customers
Pharmaceutical companies, contract manufacturers, drug delivery researchers
Industry Verticals
Pharmaceuticals, Drug Delivery, Contract Manufacturing
Competitors
FabRx, Aprecia Pharmaceuticals, MERCK
Growth & Milestones
Growth Metrics
Planning NASDAQ IPO; Multiple drug candidates in development pipeline; Strategic partnership with Evonik for manufacturing
Major Milestones
2017: Founded in Switzerland; 2021: Relocated HQ to US for planned NASDAQ IPO; 2022-03: Strategic investment and partnership with Evonik Venture Capital; 2024-06: Presented at BIO San Diego; 2025-12: Published LXM.5 study showing >380% bioavailability vs Sinemet for Parkinson's treatment
Notable Customers
Evonik Industries (manufacturing partner), Pharmaceutical companies seeking novel drug delivery solutions